Overview

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
One objective of this study is to determine the levels of markers of inflammation on the eyelid margin of subjects with blepharoconjunctivitis and compare them with those of healthy volunteers. Another objective is to determine in subjects with blepharoconjunctivitis the effect of azithromycin ophthalmic solution, 1 % on markers of inflammation of lid margins and conjunctivae and on signs and symptoms of blepharoconjunctivitis.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Azithromycin
Ophthalmic Solutions
Pharmaceutical Solutions